Elena Christofides, MD, FACE
Basic profileColumbus Oncology and Hematology Associates
Elena Christofides is an Endocrinology/Metabolic physician affiliated with Columbus Oncology and Hematology Associates. OpenAlex indexes 10 publications with 852 citations (h-index 6); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Sponsor: Gan and Lee Pharmaceuticals, USA
- Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Sponsor: Gan and Lee Pharmaceuticals, USA
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
253 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
253 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
43.7%GLP-1 receptor agonist14.7%Mounjaro37%Ozempic37%Trulicity26%Part D≥12 patientsThiazolidinedione11.7%Pioglitazone Hcl89%Pioglitazone-Metformin11%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
23%l-Thyroxine14.1%Synthroid100%Part D≥47 patientsRecombinant Human Growth Hormone4%Genotropin59%Omnitrope41%Part D<11 patients+ 2 more classes in this area
Cardiovascular
18.4%Statin5.2%Atorvastatin Calcium100%Part D≥20 patientsOmega-3 / fibrate3.8%Omega-3 Acid Ethyl Esters100%Part D≥13 patients+ 7 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Erin Macrae, MD
Columbus Oncology and Hematology Associates
Peter Kourlas, MD
Columbus Oncology and Hematology Associates
Jarred Burkart, MD
Columbus Oncology and Hematology Associates
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”